the SG opinion on enox, strong glatopa approval (FDA was a lot less revealing than enox...seems like MNTA should have a good run as sole Gx) & launch and biosim partnership by EOY are what brought me back in (my cost avg is currently higher than the current price unfortunately ;)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.